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Pedro J Romero1*, Tara Withington2 and Francesco Marincola3The field of cancer immunology and immunotherapy
is experiencing a tremendous increase in excitement
and momentum, catalyzed by the latest approvals of
immunotherapy-based treatments in multiple cancer
types. Contributing to the excitement, more cancer vac-
cine candidates, immunomodulatory monoclonal anti-
bodies and cellular therapies are showing great promise
and major pharma companies are driving their develop-
ment into future novel cancer treatments.
Through extensive research and discussion among
both the base and the leadership of the Society for Im-
munotherapy of Cancer (SITC) in the last several years,
it became clear to SITC that there was a need for a
targeted and broadly-accessible publication platform
dedicated to advancing the science of tumor immun-
ology and cancer immunotherapy. To fulfill this need
and enrich communication between the many stake-
holders in the tumor immunology and cancer immuno-
therapy community, SITC has created the Journal for
ImmunoTherapy of Cancer (JITC). This new journal will
serve the cancer immunotherapy community, to be our
community’s outlet for the publication of original re-
search articles, literature reviews, opinion/position pa-
pers and to be the prime forum to discuss the critical
issues in tumor immunology and cancer immunotherapy
research. The editorial board was constituted to bring
together outstanding leaders in both basic and clinical
tumor immunology and cancer immunotherapy fields,
and will be focused on processing manuscripts and
steering the journal in its initial stages in close collabor-
ation with SITC. The journal is owned by the SITC. It is
a joint venture with BioMed Central (BMC) -- a major
power house in open access publishing, which organizes
250 peer-reviewed open access journals.* Correspondence: pedro.romero@unil.ch
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First, we strive to publish high quality papers after an
efficient peer review process that adheres to the princi-
ples of fairness and scientific excellence. We welcome
original contributions in the following areas:
 Basic Tumor Immunology – Edited by Cornelis J.M.
Melief, ISA Therapeutics BV, The Netherlands. This
section will cover innate and adaptive anti-tumor
immune mechanisms, immune regulation, immune
response, cancer and inflammation, tumor antigens,
preclinical models, chemotherapy and radiotherapy
interactions with the anti-tumor immune response.
 Clinical/Translational Cancer Immunotherapy –
Edited by F. Stephen Hodi, Jr., Dana Farber Cancer
Institute, Boston. This section will cover first in man
clinical trials, phase II/III clinical studies of
immunotherapy, combination therapy, cell therapy,
oncolytic viruses; immune monitoring investigations,
tumor microenvironment, host genetics and clinical
outcome and updates on current clinical trials.
 Immunotherapy Biomarkers – Edited by Lisa H.
Butterfield, University of Pittsburgh Cancer
Institute. This section will cover predictive and
prognostic biomarker studies relating to
immunotherapy, including cellular, serologic, tissue
and gene expression studies in cancer
immunotherapy as well as mechanisms of action.
 Moreover, JITC is happy to publish topical reviews,
points of view articles and hypotheses in a section
edited by Thomas F. Gajewski, University of
Chicago and Bernard A. Fox, Earle A. Chiles
Research Institute, Providence Cancer Center,
Portland to trigger discussion on hot topics and
innovative concepts in the field.
Second, JITC offers immediate wide visibility for the
articles appearing online. All papers published in JITCl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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spread across institutions worldwide. In addition to this,
those articles will also be afforded high exposure across
BMC’s websites and to their extensive readership. Thus,
authors can be certain that their articles will be immediately
visible to the entire cancer immunology and immunother-
apy community. This certainly ensures immediate and wide
impact with all our peers.
Third, for the first time, our authors will enjoy all the
advantages offered by open access publishing with a
worldwide outreach. All articles are freely and univer-
sally accessible online, so an author’s work is available to
readers at no cost and not limited by their library’s
budget. This ensures that author’s work is disseminated
to the widest possible audience.
Open access journals have the potential to reach a
much larger set of readers than any subscription-based
journal, in print and online [1]. Some studies have sug-
gested a correlation between open access, higher down-
loads and higher citations, leading to a higher Impact
Factor [2,3]. Authors hold copyright for their work and
grant anyone the right to reproduce and disseminate the
article, provided that it is correctly cited and no errors
are introduced. The journal’s articles are archived in
PubMed Central [4], and other freely accessible full-text
repositories. This complies with the policies of a number
of funding bodies including the Wellcome Trust, NIH
and Howard Hughes Medical Institute [5-8]. A country’s
economy will not influence its researchers’ ability to ac-
cess articles because resource-poor countries (and insti-
tutions) will be able to read the same material as
wealthier ones (although creating access to the internet
is another matter [9]).
As part of SITC’s commitment to give the tumor im-
munology and cancer immunotherapy community a po-
tent tool of scientific and scholar communication, the
Society will be completely covering the publishing fees
to its members during the inaugural first year of JITC.
We of course also welcome nonmember submissions.
For the latter, we would like to emphasize that article
processing charges cover the cost of the publication
process to allow free and immediate access to your re-
search articles. It is a flat fee and there are no add-
itional charges for color figures, movies or large
datasets. These charges ensure transparency and allow
the publisher to compete to provide the best service
and the best price.
We will be working very hard to make JITC the prime
venue for publishing the latest results coming from the
laboratories and research groups not only of SITC mem-
bers, but also from the broader cancer immunology
community. In addition, we will utilize this outlet as a
powerful lever to advance the science and the biomed-
ical applications of tumor immunology. Your EditorialBoard is looking forward to reviewing and publishing
your papers in the exciting years to come.
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